» Articles » PMID: 34572354

Insights into the Pathogenesis of HS and Therapeutical Approaches

Overview
Journal Biomedicines
Date 2021 Sep 28
PMID 34572354
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Hidradenitis suppurativa (HS) is a debilitating, chronic, (auto)inflammatory disease primarily affecting apocrine gland-rich areas of the body. Although pathogenic mechanisms responsible for HS have not yet been fully elucidated, it is a multifactorial process whose main target is the terminal follicle. The role of the inflammatory process (and consequently of cytokine milieu) and of several other factors (genetics, lifestyle, hormonal status, microbiome, innate and adaptive immune systems) involved in HS pathogenesis has been investigated (and often defined) over the years with a view to transferring research results from bench to bedside and describing a unique and universally accepted pathogenetic model. This review will update readers on recent advances in our understanding of HS pathogenesis and novel (potential) medical therapies for patients with moderate-to-severe HS.

Citing Articles

Beyond the skin: endocrine, psychological and nutritional aspects in women with hidradenitis suppurativa.

Dattolo A, Torres M, Frias-Toral E, Paganelli A, Zhang M, Madonna S J Transl Med. 2025; 23(1):167.

PMID: 39930474 PMC: 11809040. DOI: 10.1186/s12967-025-06175-1.


Unlocking the Mechanisms of Hidradenitis Suppurativa: Inflammation and miRNA Insights.

Ames E, Sanders M, Jacobs M, Vida T Clin Cosmet Investig Dermatol. 2024; 17:2829-2846.

PMID: 39677852 PMC: 11646389. DOI: 10.2147/CCID.S483871.


Dietary Factors and Hidradenitis Suppurativa.

Shen A, Johnson J, Kerns M Dermatol Ther (Heidelb). 2023; 13(12):3007-3017.

PMID: 37899421 PMC: 10689602. DOI: 10.1007/s13555-023-01056-1.


Hidradenitis Suppurativa: An Interdisciplinary Problem in Dermatology, Gynecology, and Surgery-Pathogenesis, Comorbidities, and Current Treatments.

Nowak-Liduk A, Kitala D, Ochala-Gierek G, Labus W, Bergler-Czop B, Pietrauszka K Life (Basel). 2023; 13(9).

PMID: 37763299 PMC: 10532726. DOI: 10.3390/life13091895.


Clinical and Ultrasonographic Characterization of Hidradenitis Suppurativa in Female Patients: Impact of Early Recognition of the Disease.

Di Cesare A, Rosi E, Amerio P, Prignano F Life (Basel). 2023; 13(8).

PMID: 37629487 PMC: 10455481. DOI: 10.3390/life13081630.


References
1.
Ardon C, Wang C, Prens E, van Straalen K . Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches. Br J Dermatol. 2020; 184(2):343-345. PMC: 7891435. DOI: 10.1111/bjd.19462. View

2.
Kovacs M, Podda M . Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018; 33(3):e140-e141. DOI: 10.1111/jdv.15368. View

3.
Tegtmeyer K, Atassi G, Zhao J, Maloney N, A Lio P . Off-Label studies on anakinra in dermatology: a review. J Dermatolog Treat. 2020; 33(1):73-86. DOI: 10.1080/09546634.2020.1755417. View

4.
Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis E . Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?. Br J Dermatol. 2018; 179(2):413-419. DOI: 10.1111/bjd.16428. View

5.
Gulliver W, Jemec G, Baker K . Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2011; 26(7):911-4. DOI: 10.1111/j.1468-3083.2011.04123.x. View